Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike

Sieglinde De Cae, Inge Van Molle, Loes van Schie, Sophie R. Shoemaker, Julie Deckers, NincyDebeuf, Sahine Lameire, Wim…

Bio€quity Europe— May 12-14, 2023 – Dublin, Ireland

Excited to be a part of the Presenting Company Class of 2023 at BioEquity: Europe 2023!

ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19 (EN/FR/NL)

ExeVir Bio and VIB-UGent’s bioRxiv pre-print reports on S2-binding camelid single-domain antibody-based drug, XVR013, that targets the Achilles’ heel in the SARS-CoV-2 viral spike

Focus on protecting the millions of immuno-compromised patients, who are most vulnerable to COVID-19